Seth Walker, MD
Pulmonary Disease · Atlanta, GANPI 1104935469
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,235 of the $12,333 with a category attached, or 83.0%. Vertex accounts for 83.0% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $10,259 and has fallen 94.3% since, to $580 in 2025.
Across 94 payments — averaging $131.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$10K
- Insmed, Inc.$467
- AstraZeneca$271
- GSK$269
- Pfizer$147
- Mylan Specialty L.p.$120
- plus $825 from 23 others
Across 12 payments — averaging $14,756 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$177K
What the payments were for
- Consulting fees$10,23583%
- Food & beverage$2,02716%
- Education$711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 1 | $10,235 |
| Insmed, Inc. | 19 | $467 |
| AstraZeneca | 13 | $271 |
| GSK | 15 | $269 |
| Pfizer | 8 | $147 |
| Mylan Specialty L.p. | 2 | $120 |
| United Therapeutics Corporation | 4 | $94 |
| Grifols USA, LLC | 2 | $69 |
| Philips North America LLC | 3 | $64 |
| Bayer | 2 | $51 |
| Amgen | 3 | $49 |
| Boehringer Ingelheim | 2 | $44 |
| Merck | 2 | $41 |
| Sanofi | 2 | $39 |
| Tactile Systems Technology Inc | 1 | $36 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| ZOLL Medical Corporation | 1 | $33 |
| Johnson & Johnson | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Novartis | 1 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $24 |
| Viatris Specialty LLC | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| AbbVie | 1 | $19 |
| Gilead | 1 | $15 |
| Resmed Corp | 1 | $13 |
| Pulmonx Corporation | 1 | $13 |
How this compares
$12,333 in reported general payments places this provider in the 80th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 35 | $455,318 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 11 | $166,478 |
| Dupixent PenDupilumab | 13 | $45,387 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $36,328 |
| Advair HfaFluticasone Propion/Salmeterol | 52 | $34,711 |
| Spiriva RespimatTiotropium Bromide | 43 | $31,801 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $15,369 |
| EliquisApixaban | 17 | $14,239 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $12,126 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $11,989 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $11,587 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $8,812 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 99 | $3,281 |
| Azithromycin | 119 | $3,063 |
| Ethambutol Hcl | 16 | $2,731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $44 | $499,109103 claims |
| Insmed, Inc.Arikayce | $467 | $166,47811 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $269 | $63,28499 claims |
| PfizerEliquis | $147 | $14,23917 claims |
| AstraZenecaBreztri Aerosphere | $271 | $12,12617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Atlanta
- Colin SwensonAtlanta$255K
- Eric FlenaughAtlanta$93K
- Gregory MartinAtlanta$88K
- Victor TsengAtlanta$55K
- Ralitza MartinAtlanta$48K
- Venkatesh LakshminarayananAtlanta$33K
- Sisir AkkineniAtlanta$21K
- Gerald StatonAtlanta$21K
- Mirza AliAtlanta$16K
- Srihari VeeraraghavanAtlanta$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.